Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Do oncologists have an incentive to prescribe expensive treatments?

Peter Ubel, MD
Meds
July 4, 2012
Share
Tweet
Share

A recent economic analysis concluded that patients with metastatic cancer value their treatments significantly more than regulators recognize, with many expensive new therapies looking like veritable bargains to most patients. Yet the study ignored the values really driving oncology spending—the warped incentives oncologists have to promote their own bottom line by prescribing expensive treatments.

Let’s start with the economic analysis, another in a series of studies by a USC team of health economists funded by a large drug company. The USC team began its work with what seems like a reasonable assumption: “The amount someone is willing to pay for a good is the best measure of its social value.”

This assumption is the basis for much economic thinking, and in most market contexts, it is a reasonable take on the situation. When I refuse to buy a pair of bike shorts at $90, for example, but purchase them when the price drops to $70, my decision making says something about the value I place on those shorts. Based on this assumption, the USC team looked at what patients were willing to pay out of pocket for cancer treatments, and calculated what value they placed on these treatments. They concluded that most cancer therapies, by this measure, are a bargain.

But when trying to determine the value of expensive medications, this assumption—that “the amount someone is willing to pay for a good is the best measure of its social value”–is hard to swallow.

For starters, the price of most medical treatments is not transparent to patients. More importantly, patients’ decisions are often not made by patients themselves, but instead are made by their doctors. Patients don’t know enough about all their treatment options to be the savviest of consumers. In my book Critical Decisions coming out this fall (HarperOne, September 2012), I write about the challenge of getting patients to share in their healthcare choices. I’ll write more about this book in upcoming posts. But briefly, the challenge of shared decision making is made steep by the emotions that often surround healthcare decisions. A patient who has just learned that he has metastatic cancer is probably not going to be emotionally prepared to do comparison shopping!

Scared patients turn to their doctors for advice.

And that is where oncologic decision making gets really messy. Because in the United States, at least, many oncologists make a good deal of their income selling drugs to their patients. Here is how it works.

Oncologists purchase intravenous chemotherapy from pharmacies. Patients then receive these drugs in the oncologists’ offices, with outpatient chemotherapy being an increasingly common setting for cancer care. The oncologists then bill patients’ insurance companies for the treatments, including billing the payer for the cost of the chemotherapy PLUS a percentage based mark-up.

Medicare, for example, receives bills from oncologists that charge 106% of the cost of the chemotherapy. Many private insurers pay even larger mark-ups, especially from oncology practices that dominate their local markets and thus have pricing leverage.

This “buy and bill” practice creates an incentive for oncologists to prescribe expensive treatments.  After all, a $6 mark-up on a $100 treatment doesn’t do much for the bottom line. But that $600 mark-up on a $10,000 treatment? Give that treatment to enough patients and we’ll soon be talking about real money.

Many oncologists vehemently deny being influenced by this financial conflict of interest. But such denials defy both logic and data. Oncologists would have to be superhuman not to be influenced, at least unconsciously, by such strong incentives. After all, there is often no single “best” way to treat any given tumor, and there’s often good reason to believe that expensive new therapies might be better than older, cheaper treatments. In the face of such uncertainty, how could oncologists avoid being influenced by the knowledge that those promising expensive new treatments also help generate so much income?

Indeed, a team of Harvard researchers examined lung cancer treatments both before and after changes in Medicare reimbursement procedures, changes that led to the 6 percent rule I discussed above. (Believe it or not, prior to 2003, oncologists made even more than 6 percent profit on most of the treatments they prescribed.) Based on the 2003 law, some chemotherapies became far less profitable for oncologists to prescribe. For instance, reimbursement for paclitaxel dropped tenfold, from a little over $2,000 to $225 per month whereas a close cousin of this drug, docataxel, remained much more expensive at around $2,500 per month.

The Harvard team discovered that the percent of lung cancer patients receiving outpatient treatment grew dramatically after 2003. In other words, patients were less likely to receive such treatments in the hospital, and more likely to receive them in the oncologist’s office where the oncologist could buy and bill. In effect, since oncologists were making less profit on each treatment they gave, they tried to make up for this loss in revenue by increasing their volume.

ADVERTISEMENT

The Harvard team discovered a second thing too—that oncologists were more likely to prescribe docataxel than they were before the reimbursement changes, at the expense (literally) of cheaper drugs like paclitaxel. They shifted to the more expensive and more profitable drug.

The USC team I described above did not cite this Harvard analysis. Perhaps they were so enamored of the idea that patients know what chemotherapy they want (because, you know, patients are so well versed on the relative pros and cons of docataxel and paclitaxel), that they overlooked the likelihood that chemotherapy decisions are primarily made by oncologists.

If we want to get better value out of medical care, we should pay for value. Giving physicians an incentive to prescribe expensive drugs is bad medicine.

Peter Ubel is a physician and behavioral scientist who blogs at his self-titled site, Peter Ubel and can be reached on Twitter @PeterUbel.  He is the author of Critical Decisions: How You and Your Doctor Can Make the Right Medical Choices Together.

Prev

Applying ADHD lessons to medical marijuana

July 4, 2012 Kevin 4
…
Next

Take the time to educate yourself before forming an opinion

July 5, 2012 Kevin 6
…

Tagged as: Medications, Oncology/Hematology

Post navigation

< Previous Post
Applying ADHD lessons to medical marijuana
Next Post >
Take the time to educate yourself before forming an opinion

ADVERTISEMENT

More by Peter Ubel, MD

  • Clinicians shouldn’t be punished for taking care of needy populations

    Peter Ubel, MD
  • Patients alone cannot combat high health care prices

    Peter Ubel, MD
  • Is the FDA too slow to handle the pandemic?

    Peter Ubel, MD

More in Meds

  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • The food-drug interaction risks your doctor may be missing

    Frank Jumbe
  • Why retail pharmacies are the future of diverse clinical trials

    Shelli Pavone
  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • 5 blind spots that stall physician wealth

      Johnny Medina, MSc | Finance
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • Why flashy AI tools won’t fix health care without real infrastructure

      David Carmouche, MD | Tech
  • Recent Posts

    • Why judgment is hurting doctors—and how mindfulness can heal

      Jessie Mahoney, MD | Physician
    • Why medical schools must ditch lectures and embrace active learning

      Arlen Meyers, MD, MBA | Education
    • Why helping people means more than getting an MD

      Vaishali Jha | Education
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
    • Why evidence-based management may be an effective strategy for stronger health care leadership and equity

      Olumuyiwa Bamgbade, MD | Physician
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 4 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • 5 blind spots that stall physician wealth

      Johnny Medina, MSc | Finance
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • Why flashy AI tools won’t fix health care without real infrastructure

      David Carmouche, MD | Tech
  • Recent Posts

    • Why judgment is hurting doctors—and how mindfulness can heal

      Jessie Mahoney, MD | Physician
    • Why medical schools must ditch lectures and embrace active learning

      Arlen Meyers, MD, MBA | Education
    • Why helping people means more than getting an MD

      Vaishali Jha | Education
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
    • Why evidence-based management may be an effective strategy for stronger health care leadership and equity

      Olumuyiwa Bamgbade, MD | Physician
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Do oncologists have an incentive to prescribe expensive treatments?
4 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...